Lv4
490 积分 2021-09-15 加入
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy
7天前
已完结
Application of Computational Techniques in Antibody Fc-Fused Molecule Design for Therapeutics
9个月前
已完结
Computational optimization of antibody humanness and stability by systematic energy-based ranking
9个月前
已完结
The present and future of bispecific antibodies for cancer therapy
10个月前
已完结
Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma
1年前
已完结
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research
1年前
已完结
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response
1年前
已完结
Multifaceted collagen-DDR1 signaling in cancer
1年前
已完结
New target DDR1: A “double-edged sword” in solid tumors
1年前
已完结
Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases
1年前
已完结
皖公网安备34019202002308
